Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 4Completed 2Withdrawn 1Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Endocrine 1CNS 1

Conditions

Prostatic Neoplasms 595Carcinoma, Renal Cell 276Urinary Bladder Neoplasms 175Kidney Neoplasms 112Neoplasms 101Neoplasm Metastasis 94Carcinoma, Non-Small-Cell Lung 94Carcinoma, Transitional Cell 86Melanoma 85Breast Neoplasms 83Ovarian Neoplasms 64Lung Neoplasms 50Colorectal Neoplasms 50Pancreatic Neoplasms 43Stomach Neoplasms 40Sarcoma 37Squamous Cell Carcinoma of Head and Neck 35Triple Negative Breast Neoplasms 31Testicular Neoplasms 29Uterine Cervical Neoplasms 27Esophageal Neoplasms 26Carcinoma, Hepatocellular 26Head and Neck Neoplasms 24Non-Muscle Invasive Bladder Neoplasms 23Small Cell Lung Carcinoma 22Colonic Neoplasms 20Urologic Neoplasms 17Neuroblastoma 17Multiple Myeloma 17Endometrial Neoplasms 17

Interventions

spartalizumab 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hereditary leiomyomatosis and renal cell cancer × Genitourinary × Clear all
NCT04895748 2026-03-03

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Novartis

Phase 1 Terminated
40 enrolled
CNSEndocrineGenitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡